在纽瓦克弗劳恩霍夫中心、德和波士顿大学开发植物性疫苗工厂IBIO表达式基于专有技术,公司。
阅读时间:
Fraunhofer Center for Molecular Biotechnology in Newark, Delaware, the Fraunhofer Center for Manufacturing Innovation in Boston, Massachusetts, the Boston University College of Engineering, and the biopharmaceutical company iBio, Inc. in Newark, Delaware, announced today that they have developed a fully automated, scalable factory that uses natural (non-genetically-modified) green plants to efficiently produce large quantities of vaccines and therapeutics within weeks.
这样一个快速疫苗生产设施将发挥至关重要的作用在解决和遏制未来的流行病和新兴生物威胁。
这第一个全新,植物疫苗工厂,利用植物病毒载体技术由弗劳恩霍夫CMB iBio生物制药公司。这项技术能够产生特定的蛋白质在快速增长的植物的叶子。The factorys robotically tended machines, designed by Fraunhofer CMI, plant seeds, nurture the growing plants, introduce a viral vector that directs the plant to produce a target protein and harvest the biomass once the target has accumulated in the plant tissue. Traditional methods of vaccine production can take many months. Our plant-based technology provides the means for rapid, large scale production of vaccine material in a cost effective manner, said Dr. Vidadi Yusibov, Executive Director of CMB. This technology has the potential to revolutionize how biological materials are manufactured. By partnering with CMI and Boston University, we engineered agricultural and molecular biology into scalable automated processes to es
tablish第一cGMP(当前良好生产规范)对植物性蛋白质生产设施。
工厂设计是时间、成本和空间效率。它有能力在一批种植成千上万的植物。植物是生长在为主托盘用于处理和运输植物不同加工站。To automate the process, robots glide up and down a track, tending the plants delivering trays from the lighted, irrigated growth modules to each processing station at the appropriate time. In order to quickly produce large quantities of vaccine material or other protein-based medicines such as antibodies in compliance with cGMP, it was necessary to develop a consistent, repeatable process. We have taken a biological process and turned it into an industrial process said Andre Sharon, a professor of mechanical engineering at Boston University and Director of CMI. Even though the process of making vaccines from plants includes many aspects of traditional horticulture such as growing, watering and harvesting, we have developed a way to automate thos
e functions to quickly, safely and cost effectively scale up from a few milligrams in a laboratory setting to the many kilograms that would be required in case of a pandemic, said Sharon. Everything was designed from the ground up. The process is faster, less expensive, safer, and does not require the sophisticated culturing or fermentation necessary in the current vaccine production
流程。
This unique, plant-based vaccine factory resulted from a three-year collaboration between the Fraunhofer USA Centers in Delaware and Boston, which are affiliated with Fraunhofer-Gesellschaft, Europes largest applied research organization, and Boston University. This is a perfect example of coupling engineering expertise and scientific advancement to cost-effectively meet a societal need, remarked Robert Brown, president of Boston University and a chemical engineer. It is a model for collaboration that we strongly believe in on our campus, as they do at Fraunhofer as well.
支持国防高级研究计划局(DARPA)根据Accerlated制造药品计划,随着资金来自特拉华州的关键在促进试验设施的设计和建造在纽瓦克,特拉华州。I am impressed by Fraunhofers innovation and commitment to excellence at the scientific and business levels. I am hopeful that Fraunhofers promising discoveries will advance vaccines and pleased that these biological state-of-the-art developments are taking place in Delaware, said Delaware Governor Jack Markell.
We believe the new factory in Delaware demonstrates that public health officials will finally have a rapid, high-performance vaccine production technology to use against emergent threats, said Robert Erwin, President of iBio. We also expect scalability and efficiency of the expression and manufacturing technology to lead to broad commercial applications.
关于弗劳恩霍夫
Fraunhofer-Gesellschaft是领先的欧洲应用研究组织与59研究机构和17000名员工。弗劳恩霍夫普利茅斯是美国全资子公司,总部位于密歇根州的研究中心合作在美国主要的大学弗劳恩霍夫分子生物技术发展中心安全、快速、经济的替代疫苗生产。中心进行植物生物技术领域的研究,利用新的前沿技术协助诊断,人类和动物疾病的预防和治疗。卓越中心房子个人专业知识和在植物病毒学、病理学、分子生物学、免疫学、疫苗、蛋白质工程,生物化学。弗劳恩霍夫制造业创新中心位于校园的,和波士顿大学的合作。该中心成立于1995年作为学术研究和工业需求之间的桥梁。布鲁里溃疡与教员和斯图
凹陷,工程师和科学家在扩大基本先进技术研究中心。中心的焦点是开发的新一代仪器和高精密自动化系统生物技术/生物医学光子学和可再生能源领域。
关于波士顿大学
波士顿大学成立于1839年,是一个国际公认的私立研究型大学,超过30000名学生参与本科生,研究生和专业项目。BU consists of 17 colleges and schools along with a number of multi-disciplinary centers and institutes which are central to the schools research and teaching mission. The BU College of Engineering offers bachelors, masters and doctoral degrees in the departments of Biomedical, Mechanical, and Electrical and Computer Engineering. It also has two interdisciplinary divisions focused on research and graduate education: the Division of Systems Engineering; and the Division of Materials Science & Engineering.
关于iBio
iBio, Inc. is a biopharmaceutical company commercializing its proprietary technology, the iBioLaunch platform, for the production of biologics including vaccines and therapeutic proteins. The iBioLaunch platform uses transient gene expression in green plants for superior efficiency in protein production. Advantages include significantly lower capital and process costs, and the technology is ideally suited to infectious disease applications where speed, scalability, and surge capacity are important. iBios strategy is to utilize its technology for development and manufacture of its own product candidates and work with both corporate and government clients to reduce their costs during product development and meet their needs for low cost, high quality biologics manufacturing systems. iBio owns technology developed at the Fraunhofer USA Center for Molecular Biotechnology, and continues to sponsor development and refinement of the technology for broad applications in human healthcare. Further information is ava
ilable www.ibioinc.com。
这样一个快速疫苗生产设施将发挥至关重要的作用在解决和遏制未来的流行病和新兴生物威胁。
这第一个全新,植物疫苗工厂,利用植物病毒载体技术由弗劳恩霍夫CMB iBio生物制药公司。这项技术能够产生特定的蛋白质在快速增长的植物的叶子。The factorys robotically tended machines, designed by Fraunhofer CMI, plant seeds, nurture the growing plants, introduce a viral vector that directs the plant to produce a target protein and harvest the biomass once the target has accumulated in the plant tissue. Traditional methods of vaccine production can take many months. Our plant-based technology provides the means for rapid, large scale production of vaccine material in a cost effective manner, said Dr. Vidadi Yusibov, Executive Director of CMB. This technology has the potential to revolutionize how biological materials are manufactured. By partnering with CMI and Boston University, we engineered agricultural and molecular biology into scalable automated processes to es
tablish第一cGMP(当前良好生产规范)对植物性蛋白质生产设施。
工厂设计是时间、成本和空间效率。它有能力在一批种植成千上万的植物。植物是生长在为主托盘用于处理和运输植物不同加工站。To automate the process, robots glide up and down a track, tending the plants delivering trays from the lighted, irrigated growth modules to each processing station at the appropriate time. In order to quickly produce large quantities of vaccine material or other protein-based medicines such as antibodies in compliance with cGMP, it was necessary to develop a consistent, repeatable process. We have taken a biological process and turned it into an industrial process said Andre Sharon, a professor of mechanical engineering at Boston University and Director of CMI. Even though the process of making vaccines from plants includes many aspects of traditional horticulture such as growing, watering and harvesting, we have developed a way to automate thos
e functions to quickly, safely and cost effectively scale up from a few milligrams in a laboratory setting to the many kilograms that would be required in case of a pandemic, said Sharon. Everything was designed from the ground up. The process is faster, less expensive, safer, and does not require the sophisticated culturing or fermentation necessary in the current vaccine production
流程。
This unique, plant-based vaccine factory resulted from a three-year collaboration between the Fraunhofer USA Centers in Delaware and Boston, which are affiliated with Fraunhofer-Gesellschaft, Europes largest applied research organization, and Boston University. This is a perfect example of coupling engineering expertise and scientific advancement to cost-effectively meet a societal need, remarked Robert Brown, president of Boston University and a chemical engineer. It is a model for collaboration that we strongly believe in on our campus, as they do at Fraunhofer as well.
支持国防高级研究计划局(DARPA)根据Accerlated制造药品计划,随着资金来自特拉华州的关键在促进试验设施的设计和建造在纽瓦克,特拉华州。I am impressed by Fraunhofers innovation and commitment to excellence at the scientific and business levels. I am hopeful that Fraunhofers promising discoveries will advance vaccines and pleased that these biological state-of-the-art developments are taking place in Delaware, said Delaware Governor Jack Markell.
We believe the new factory in Delaware demonstrates that public health officials will finally have a rapid, high-performance vaccine production technology to use against emergent threats, said Robert Erwin, President of iBio. We also expect scalability and efficiency of the expression and manufacturing technology to lead to broad commercial applications.
关于弗劳恩霍夫
Fraunhofer-Gesellschaft是领先的欧洲应用研究组织与59研究机构和17000名员工。弗劳恩霍夫普利茅斯是美国全资子公司,总部位于密歇根州的研究中心合作在美国主要的大学弗劳恩霍夫分子生物技术发展中心安全、快速、经济的替代疫苗生产。中心进行植物生物技术领域的研究,利用新的前沿技术协助诊断,人类和动物疾病的预防和治疗。卓越中心房子个人专业知识和在植物病毒学、病理学、分子生物学、免疫学、疫苗、蛋白质工程,生物化学。弗劳恩霍夫制造业创新中心位于校园的,和波士顿大学的合作。该中心成立于1995年作为学术研究和工业需求之间的桥梁。布鲁里溃疡与教员和斯图
凹陷,工程师和科学家在扩大基本先进技术研究中心。中心的焦点是开发的新一代仪器和高精密自动化系统生物技术/生物医学光子学和可再生能源领域。
关于波士顿大学
波士顿大学成立于1839年,是一个国际公认的私立研究型大学,超过30000名学生参与本科生,研究生和专业项目。BU consists of 17 colleges and schools along with a number of multi-disciplinary centers and institutes which are central to the schools research and teaching mission. The BU College of Engineering offers bachelors, masters and doctoral degrees in the departments of Biomedical, Mechanical, and Electrical and Computer Engineering. It also has two interdisciplinary divisions focused on research and graduate education: the Division of Systems Engineering; and the Division of Materials Science & Engineering.
关于iBio
iBio, Inc. is a biopharmaceutical company commercializing its proprietary technology, the iBioLaunch platform, for the production of biologics including vaccines and therapeutic proteins. The iBioLaunch platform uses transient gene expression in green plants for superior efficiency in protein production. Advantages include significantly lower capital and process costs, and the technology is ideally suited to infectious disease applications where speed, scalability, and surge capacity are important. iBios strategy is to utilize its technology for development and manufacture of its own product candidates and work with both corporate and government clients to reduce their costs during product development and meet their needs for low cost, high quality biologics manufacturing systems. iBio owns technology developed at the Fraunhofer USA Center for Molecular Biotechnology, and continues to sponsor development and refinement of the technology for broad applications in human healthcare. Further information is ava
ilable www.ibioinc.com。
广告
